Galectin Therapeutics Inc
(NAS:GALT)
$
1.1101
-0.0399 (-3.47%)
Market Cap: 69.67 Mil
Enterprise Value: 152.25 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 31/100 Galectin Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023 / 02:30PM GMT
Release Date Price:
$1.66
(-2.92%)
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Great. Well, we'll get started. Our next presenting company is Galectin Therapeutics. And joining us is the President and CEO, Joel Lewis; as well as Pol Boudes, the Chief Commercial Officer -- sorry, Medical Officer.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
He can be the Chief Commercial Officer too.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
Good, good. Welcome, both of you.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
Thank you.
Pol Boudes
Galectin Therapeutics Inc. - Chief Medical Officer
Welcome.
Ed Arce
H. C. Wainwright & Co., LLC - Analyst
So I wanted to start if you could just briefly introduce the company and its strategy.
Joel Lewis
Galectin Therapeutics Inc. - CEO & President
Sure. First of all, thank you to Ed and H.C.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot